Sirtex develops & delivers interventional oncology treatments using novel small particle technology to improve outcomes for patients with metastatic colorectal cancer. SIR-Spheres® Y-90 resin microspheres target liver tumors with radiation via the hepatic artery during SIRT. SIRFLOX data showed a statistically significant improvement of 7.9 months in median PFS in the liver for patients with unresectable mCRC treated first line with SIR-Spheres Y-90 resin microspheres plus standard chemotherapy.